SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 


 

Date of Report (Date of earliest event reported):  December 2, 2003

 

Anika Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Massachusetts

 

000-21326

 

04-3145961

(State or Other Jurisdiction of
Incorporation or Organization)

 

(Commission file
Number)

 

(I.R.S. Employer Identification No.)

 

 

 

 

 

160 New Boston Street, Woburn, Massachusetts

 

01801

(Address of Principal Executive Offices)

 

(Zip Code)

 

 

 

Registrant’s Telephone Number, Including Area Code: (781) 932-6616

 

 



 

Item 5:  Other Events and Required FD Disclosure.

 

On December 2, 2003, Anika Therapeutics, Inc. issued a press release (“Press Release”) announcing that it had received an approvable letter from the U.S. Food and Drug Administration regarding its ORTHOVISCÒ osteoarthritis product.  A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference in its entirety.

 

Item 7:  Financial Statements, Pro Forma Financial Information and Exhibits.

 

(c) Exhibits

 

Exhibit No.

 

Description

99.1

 

Press Release issued by Anika Therapeutics, Inc. on December 2, 2003

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

ANIKA THERAPEUTICS, INC.

 

 

December 2, 2003

By:

/s/  Charles H. Sherwood

 

 

 

Charles H. Sherwood, Ph.D.

 

 

Chief Executive Officer and President

 

3



 

Exhibit Index

 

Exhibit No.

 

Description

99.1

 

Press Release of Anika Therapeutics, Inc. dated December 2, 2003

 

4